Amivantamab plus pembrolizumab and carboplatin in R/M HNSCC: Evaluating improved response and survival vs chemo

Talazoparib plus enzalutamide improves radiographic progression-free survival in HRR-altered mCSPC

Sacituzumab govitecan improves PFS across Trop-2, BRCA, and HER2 metastatic triple-negative breast cancer

Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer

1: Safe administration and dosing of EGFR inhibitors in NSCLC - Practical guidance for oncology nurses

2: Managing EGFR inhibitor side effects in NSCLC - Skin toxicity impact, adherence challenges, and nursing management

3: MDT collaboration in NSCLC - Aligning oncologists, nurses, and patients to enhance EGFR inhibitor treatment pathways and supportive care

ASCO 2026: Highlights and analysis

Velzatinib demonstrates broad activity across KIT mutations in advanced gastrointestinal stromal tumours

Optimal panitumumab–bevacizumab sequencing evaluated in RAS wild-type metastatic colorectal cancer

Bupropion shows benefit for cancer-related fatigue in cancer survivors

Relacorilant chemo combination extends OS in platinum-resistant ovarian cancer